TransCon hGH

Phase 3Small molecule

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

TransCon hGH is a small molecule that works as a Long-Acting Growth Hormone Prodrug.[2] It is being investigated across 3 indications, with its most advanced program in Phase 3.[1]

TransCon hGH is one of 82 prodrug programs targeting Hypoparathyroidism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoparathyroidismActive, not recruiting

Growth Hormone DeficiencyUnknown

GrowthCompleted

HypoparathyroidismPhase 3

Active, not recruiting

Growth Hormone DeficiencyPreclinical

Unknown

GrowthPhase 3

Completed

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

TransCon hGH

VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Phase 3

2 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Lenvima

Eisai

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Somavaratan

Glucophage

2 10

EGRIFTA WR

TTheratechnologies

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth2 trials

enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial

Completed·AAscendis Pharma A/S·Phase 3·NCT03344458·298 enrolled

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Completed·AAscendis Pharma Endocrinology Division A/S·Phase 3·NCT03305016·146 enrolled

Hypoparathyroidism1 trial

PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

Completed·VVisen Pharmaceuticals (Shanghai) Co., Ltd.·Phase 3·NCT05387070·81 enrolled

Growth Hormone Deficiency1 trial

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

Unknown status·VVisen Pharmaceuticals (Shanghai) Co., Ltd.·Phase 3·NCT04326374·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TransCon hGH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TransCon hGH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TransCon hGH. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 1 publication indexed for TransCon hGH. U.S. National Library of Medicine.
[5]
SEC EDGAR — Visen Pharmaceuticals (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Long-Acting Growth Hormone Prodrug[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVisen Pharmaceuticals (Shanghai) Co., Ltd.

Key Publications[4]

Weekly TransCon hGH in Pediatric Growth Hormone Deficiency: Phase 3

J Clin Endocrinol MetabDec 1, 2022DOI: 10.1210/clinem/dgac654

TransCon hGH

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth2 trials

Hypoparathyroidism1 trial

Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News